U.S. markets closed
  • S&P 500

    +51.87 (+1.60%)
  • Dow 30

    +358.56 (+1.34%)
  • Nasdaq

    +241.26 (+2.26%)
  • Russell 2000

    +23.09 (+1.59%)
  • Crude Oil

    -0.27 (-0.67%)
  • Gold

    -12.60 (-0.67%)
  • Silver

    -0.21 (-0.91%)

    -0.0038 (-0.33%)
  • 10-Yr Bond

    -0.0070 (-1.05%)

    -0.0007 (-0.06%)

    +0.0980 (+0.09%)

    -69.31 (-0.65%)
  • CMC Crypto 200

    +12.36 (+5.67%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.82 (+0.51%)

Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401

Stock Monitor: Cyclacel Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML) ("Stemline"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On April 05, 2018, the Company, which is a clinical-stage biopharmaceutical organization developing novel oncology therapeutics, declared that it has started its rolling submission of a Biologics License Application (BLA) for SL-401 to the US Food and Drug Administration (FDA). Register today and get access to over 1000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), which also belongs to the Healthcare sector as the Company Stemline Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Stemline Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


About SL-401

SL-401 is one of the clinical stage product candidates of Stemline. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a range of malignancies. SL-401 has completed a pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), wherein it met its primary endpoint. Moreover, the FDA has granted a Breakthrough Therapy Designation (BTD) to SL-401 in BPDCN.

Besides, the product candidate is also being evaluated in clinical trials in additional indications such as chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and myeloma.

A Major Milestone for SL-401

Ivan Bergstein, MD, Chief Executive Officer (CEO) of Stemline, believes that the start of the rolling BLA submission is a significant milestone for the Company and the BPDCN patient community.

If SL-401 gets approved, it would be the first-drug ever approved for BPDCN and would have a transformative impact on the lives of patients suffering with this malignant disease. Looking forward, the Company intends to continue its clinical, regulatory, manufacturing, and commercial work to bring SL-401 to patients as soon as possible.

Stemline Reported Fourth Quarter 2017 Results

Stemline reported its financial results on March 16, 2018, for the fourth quarter and full fiscal year ended December 31, 2017.

  • The Company had a net loss of $21.75 million, or $0.93 loss per share, in Q4 FY17, compared to a net loss of $10.0 million, or $0.56 loss per share, in the same period of 2016.

  • The Company's operating expenses were $21.94 million in the reported quarter versus $10.43 million in the previous year's comparable quarter. The Company's research and development (R&D) expenses advanced 129.61% to $16.73 million y-o-y, and its general and administrative (G&A) expenses increased 65.91% to $5.21 million y-o-y in Q4 FY17.

  • Stemline had cash, cash equivalents, and investments of $66.2 million, 17.15% lower than $79.9 million as of September 30, 2017. The Company incurred a total capital expenditure of $13.7 million in the quarter under review.

  • During January 2018, Stemline completed a follow-on public offering, raising $55.5 million in net cash proceeds, which brought its total cash, cash equivalents, and investments to approximately $106.8 million as on March 16, 2018.

  • For the full fiscal year ended December 31, 2017, Stemline generated revenues of $0.9 million, 13.75% lower than $1.04 million in FY16. The Company incurred a net loss of $67.83 million in the reported year, 77.08% higher than $38.30 million in FY16.

Stock Performance Snapshot

April 06, 2018 - At Friday's closing bell, Stemline Therapeutics' stock was slightly down 0.66%, ending the trading session at $15.10.

Volume traded for the day: 212.28 thousand shares.

Stock performance in the previous six-month period – up 31.30%; and past twelve-month period – up 94.84%

After last Friday's close, Stemline Therapeutics' market cap was at $451.79 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors